Business context and reporting period
Filing-identity note: The supplied filing is Aerovate Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2023, not a filing for Jade Biosciences, Inc. The summary below reflects the filing provided.
Aerovate is a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It has no approved products and has generated no product revenue. The results below compare Q3 and the first nine months of 2023 with the corresponding 2022 periods.
Financial results and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $16.9m | $10.8m | $46.4m | $26.4m |
| General and administrative expense | $4.5m | $3.4m | $12.9m | $11.0m |
| Total operating expenses | $21.4m | $14.2m | $59.3m | $37.4m |
| Net loss | $19.6m | $13.6m | $55.1m | $36.5m |
| Interest income | $1.8m | $0.6m | $4.2m | $0.9m |
| Basic and diluted loss per share | $0.71 | $0.56 | $2.13 | $1.49 |
As of September 30, 2023, cash and cash equivalents were $32.2m and short-term investments were $103.0m, totaling approximately $135.2m. Total assets were $140.9m, total liabilities $15.2m, and stockholders’ equity $125.7m. The filing reports no long-term debt; operating lease liabilities totaled $0.8m. No operating margin is meaningful because the company had no revenue.
For the nine months, operating cash use was $42.0m, investing activities provided $6.2m (mainly net maturities of short-term investments), and financing provided $45.5m, primarily from common-stock sales under the ATM program. Cash and cash equivalents increased $9.8m to $32.2m. The company sold 2.66m shares under its ATM program for approximately $44.3m in net proceeds; up to $30.0m remained available under the program at September 30.
Changes versus the prior comparable period
Q3 operating expenses increased $7.2m year over year, led by higher R&D costs, including headcount, contract manufacturing, and clinical-trial spending. Nine-month R&D expense rose $20.0m, reflecting increased clinical-trial costs, staffing, and manufacturing. Nine-month G&A expense increased $2.0m. Higher interest income partly offset the increased expenses, but the nine-month net loss widened by $18.6m. The share count also increased: 27.65m shares were outstanding at September 30, 2023, versus 24.72m at December 31, 2022.
Outlook, commentary, risks, and unusual items
Management said available cash, cash equivalents, and securities were expected to fund planned operations into 2026, while noting that forecasts are uncertain and that additional capital may be needed. The filing also says current resources were expected to cover obligations for at least 12 months from the filing date. The company anticipates substantial losses and increased R&D spending; it has no product-sales revenue and may need further financing.
Management expected topline data from the Phase 2b portion of the global IMPAHCT trial in Q2 2024 and anticipated completing enrollment about seven months earlier. Enrollment and site activation had been affected by staffing shortages and interruptions at trial sites and CROs. AV-101 is the company’s only product candidate; its efficacy and tolerability in PAH patients remain unproven. The filing highlights clinical, regulatory, manufacturing and supplier, financing, competition, intellectual-property, and patient-enrollment risks. Oral imatinib showed clinical effects in a prior PAH trial but had tolerability challenges; results may not predict AV-101 outcomes.
There were no material legal proceedings reported. Management concluded disclosure controls and procedures were effective at a reasonable assurance level and reported no material changes in internal control over financial reporting during the quarter. Unrealized investment losses were attributed to market-value and interest-rate changes, not credit losses; no investment impairment losses were recorded.
Important facts for investors to verify
- Confirm the intended issuer: this is Aerovate Therapeutics’ filing, not Jade Biosciences’.
- Check subsequent disclosures for IMPAHCT enrollment progress, trial timing, and Phase 2b results; the stated Q2 2024 timing was a forward-looking expectation.
- Assess cash consumption and runway against the differing statements of funding into 2026 and coverage for at least 12 months from filing.
- Review remaining ATM capacity, subsequent share issuance, and dilution, as well as future financing needs.
- Monitor AV-101’s patient safety and efficacy data, regulatory pathway, and manufacturing and trial-site dependencies.